Annual Revenue Comparison: Takeda Pharmaceutical Company Limited vs Telix Pharmaceuticals Limited

Takeda vs. Telix: A Decade of Revenue Growth

__timestampTakeda Pharmaceutical Company LimitedTelix Pharmaceuticals Limited
Wednesday, January 1, 2014177782400000028336824
Thursday, January 1, 2015180737800000032319194
Friday, January 1, 2016173205100000029404631
Sunday, January 1, 2017177053100000031769230
Monday, January 1, 2018209722400000020439380
Tuesday, January 1, 2019329118800000024186536
Wednesday, January 1, 202031978120000004680000
Friday, January 1, 202135690060000004898000
Saturday, January 1, 20224027478000000155984000
Sunday, January 1, 20234263762000000496659000
Monday, January 1, 20244263762000000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceuticals: Takeda vs. Telix

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of a company's success. Over the past decade, Takeda Pharmaceutical Company Limited has demonstrated a robust upward trajectory, with its annual revenue increasing by approximately 140% from 2014 to 2023. In contrast, Telix Pharmaceuticals Limited, a relatively newer player, has shown promising growth, albeit on a smaller scale, with a revenue increase of over 1,600% during the same period.

Takeda's revenue surged significantly in 2019, marking a pivotal year with a 57% increase, likely due to strategic acquisitions and expansions. Meanwhile, Telix's revenue saw a remarkable spike in 2023, reflecting its growing influence in the biotech sector. However, data for 2024 remains incomplete, leaving room for speculation on future trends.

This comparison highlights the dynamic nature of the pharmaceutical landscape, where established giants and emerging innovators coexist and compete.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025